Inari Medical, Inc. (NASDAQ:NARI) Q3 2023 Earnings Call Transcript

Mitch Hill: Thanks for the question, Chris. So just to be clear, LimFlow is a technology that’s really appropriate for what we call no option patients. These are patients who don’t have any option for traditional revascularization, angioplasty, surgery, anything like that. The Rutherford class is the level of current symptomatology of the patient. So the added opportunity in Rutherford for our patients who are somewhat less symptomatic but still are no option in terms of their revascularization. So what we would be displacing is simply conservative therapy, watchful waiting, and amputation.

Chris Pasquale: That’s helpful. Thanks for clarifying that. And then on the existing business, REVCORE seems like it’s off to a strong start. I’m curious whether you think you’re picking up cases there that you would not otherwise be involved in, or if it’s just providing a better solution in procedures that you would have been in already, trying to understand how incremental that product really is.

Mitch Hill: Yeah, so I’ll tackle that one as well. I think the REVCORE product is completely incremental to our VTE business. These are patients who have occluded venous stents. There is currently no approved option for treatment of those patients other than for REVCORE. I think what those patients might be getting in an off-label fashion prior to REVCORE is conservative therapy or angioplasty and relining with stent, which we know is a terrible solution from a lot of other disease states. So I think all of the RebCorp business that we’re doing is incremental.

Chris Pasquale: Great. Thank you.

Operator: There are no more questions in the queue. This concludes our question-and-answer session, and the conference is now concluded. Thank you for attending today’s presentation. You may now disconnect